Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema vs semaglutide in East Asian obesity
NCT05813925Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2023
- Primary completion
- Jan 2025
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of cagrilintide in obesity (2 arms), sponsored by Novo Nordisk. Primary endpoint: Relative Change in Body Weight at 68 weeks. Started Apr 2023; status: completed.
02
Drugs
cagrilintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05813925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813925.